ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Aldeyra Stockholders and Encourages Investors to Contact the Firm

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Aldeyra Therapeutics for possible violations of federal securities laws and unlawful business practices [1] - Aldeyra received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, indicating that the application failed to demonstrate efficacy in treating dry eye disease and requires additional studies [2] Company Summary - Aldeyra Therapeutics is facing scrutiny after the FDA's response highlighted concerns about the efficacy of reproxalap, which may impact the company's stock performance [2] - The FDA's letter pointed out methodological issues in the trial data submitted, which could have affected the interpretation of results [2] Legal and Investor Relations - The law firm is reaching out to Aldeyra stockholders who may have suffered losses and is encouraging them to participate in the investigation [3] - Bragar Eagel & Squire, P.C. specializes in representing investors in complex litigation, indicating a focus on protecting shareholder rights [4]